Allianz Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Allianz Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-581,489	Closed	-$21.2M	–	2355
2014 Q2	$21.2M	Sell	581,489 -166,582	-22%	-$6.72M	0.03%	544
2014 Q1	$34.3M	Sell	748,071 -24,354	-3%	-$1.14M	0.04%	421
2013 Q4	$30M	Buy	772,425 +6,390	+0.8%	+$269K	0.04%	453
2013 Q3	$34.7M	Buy	766,035 +55,315	+8%	+$2.84M	0.05%	407
2013 Q2	$34.9M	Buy	+710,720	New	+$37.7M	0.05%	391

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Allianz Asset Management's PLX Position: Q3 2014 in Review

Allianz Asset Management sold out of Protalix BioTherapeutics (PLX) in Q3 2014, closing a stake of 581,489 shares — an estimated $21.2M sold.

Allianz Asset Management first reported a position in PLX in Q2 2013 and held it in 5 quarters. The position peaked at $34.9M in Q2 2013. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

Allianz Asset Management reported no remaining Protalix BioTherapeutics position as of Q3 2014 after selling out during the quarter.
Allianz Asset Management sold 581,489 Protalix BioTherapeutics shares in Q3 2014, an estimated $21.2M.
Allianz Asset Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 5 quarters.
Allianz Asset Management's Protalix BioTherapeutics position peaked at $34.9M in Q2 2013.
43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on Allianz Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.